Indicators of immune status in the blood of patients depending on the stage of atrophic gastritis according to the OLGA system


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Development of a gradation of precancerous lesions is aimed at improving the secondary prevention of neoplasms. This is facilitated by the search for factors that allow stratifying the severity of manifestations of atrophic gastritis (AG). Objective. The evaluation of indicators of the immune status in the blood of patients depending on the stage of AG according to the OLGA system. Methods. The study included 125 patients aged 18 to 80 years: 52 healthy volunteers (26 men and 26 women, mean age 48.2±4.0 years) undergoing annual medical examinations at the Research Institute of Medical Problems of the North, Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences", and 73 patients with AG (38 men and 35 women, mean age - 49.9±4.6 years). Healthy patients were determined on the basis of the absence of a gastroenterological medical history and clinical symptoms of digestive diseases, the blood pepsinogen-1 (PG-1) level >50 pg/L, and the PG-1/PG-2 ratio >3. All patients were H. pylori-positive. The diagnosis of AG was established by a gastroenterologist on the basis of a clinical examination, the presence of H. pylori infection and detection of atrophy of the gastric mucosa during histological examination. All patients underwent a standard clinical examination by a gastroenterologist and laboratory and instrumental studies. Fiberoptic esophagogastroduodenos-copy with a sampling of 5 biopsy specimens from the gastric mucosa was performed in 73 AG patients. Evaluation of AG was carried out according to the OLGA system in histological preparations stained with hematoxylin-eosin. H. pylori was determined by histological method in preparations stained by Romanowsky-Giemsa method. The study of the immune status included determining the number of leukocytes and lymphocytes and indicators of cellular immunity by indirect immunofluorescence of lymphocytes using monoclonal antibodies to CD3, CD4, CD8, CD16, CD19 (Sorbent LLP, Moscow). Results. Compared to healthy individuals, patients with stage III - IV chronic atrophic gastritis according to the OLGA system had inhibition of the T-cell immunity, manifested by a decrease in the absolute number of leukocytes and lymphocytes; a decrease in the absolute and relative levels of mature T-lymphocytes, CD4+ cells, immunoregulatory index (CD4+/CD8+) and NK cells. Impaired cellular immunity was associated with an increase in the stage of atrophy according to the OLGA system. Conclusion. The combination of the use of the OLGA morphological system with the determination of immune parameters increases the possibility of stratification of AG to determine the risk of developing gastric cancer.

Full Text

Restricted Access

About the authors

Vladislav V. Tsukanov

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Email: gastro@impn.ru
Dr. Sci. (Med.), Professor, Head of the Clinical Department of Pathology of Digestive System in Adults and Children, Scientific Research Institute of Medical Problems of the North Krasnoyarsk, Russia

A. V Vasyutin

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Research Institute of Medical Problems of the North Krasnoyarsk, Russia

Yu. L Tonkikh

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Research Institute of Medical Problems of the North Krasnoyarsk, Russia

O. V Smirnova

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Research Institute of Medical Problems of the North Krasnoyarsk, Russia

A. A Sinyakov

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Research Institute of Medical Problems of the North Krasnoyarsk, Russia

N. G Elmanova

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences"

Research Institute of Medical Problems of the North Krasnoyarsk, Russia

References

  1. Gupta S., Tao L., Murphy J.D., et ai. Race/ Ethnicity-, Socioeconomic Status-, and Anatomic Subsite-Specific Risks for Gastric Cancer Gastroenterology. 2019;156(1):59-62. doi: 10.1053/j.gastro.2018.09.045.
  2. Venerito M., Link A., Rokkas T., Maifertheiner P Review: Gastric cancer-Ciinicai aspects. Helicobacter. 2019;24(1):e12643. Doi: 10.1111/ hei.12643.
  3. Piiieron S., Sarfati D., Janssen-Heijnen M., et ai. Giobai cancer incidence in oider aduits, 2012 and 2035: A popuiation-based study Int J Cancer. 2019;144(1):49-58. doi: 10.1002/ijc.31664.
  4. Sugano K. Effect of Heiicobacter pyiori eradication on the incidence of gastric cancer: a systematic review and meta-anaiysis. Gastric Cancer. 2019;22(3):435-45. doi: 10.1007/s10120-018-0876-0.
  5. Kaji K., Hashiba A., Uotani C., et al. Grading of Atrophic Gastritis is Usefui for Risk Stratification in Endoscopic Screening for Gastric Cancer. Am J Gastroenteroi. 2019;114(1):71-9. doi: 10.1038/s41395-018-0259-5.
  6. Rugge M., Sacchi D., Graham D.Y., Genta R.M. Secondary prevention of gastric cancer: merging the endoscopic atrophic border with OLGA staging. Gut. 2019 Jun 11. Doi: 10.1136/ gutjnl-2019-319107.
  7. Rugge M., Sugano K., Scarpignato C., et al. Gastric cancer prevention targeted on risk assessment: Gastritis OLGA staging. Helicobacter 2019;24(2):e12571. doi: 10.1111/hel.12571.
  8. Kuhns M.S., Badgandi H.B. Piecing together the family portrait of TCR-CD3 complexes. Immunol Rev. 2012;250(1):120-43. Doi: 10.1111/ imr. 12000.
  9. Zhu J., Paul W.E. Heterogeneity and plasticity of T helper cells. Cell Res. 2010;20(1):4-12. doi: 10.1038/cr.2009.138.
  10. Kikete S., Chu X., Wang L., Bian Y Endogenous and tumour-derived microRNAs regulate crosspresentation in dendritic cells and consequently cytotoxic T cell function. Cytotechnology. 2016;68(6):2223-33. doi: 10.1007/s10616-016-9975-0.
  11. Sharma P, Kumar P, Sharma R. Natural Killer Cells - Their Role in Tumour Immunosurveillance. J Clin Diagn Res. 2017;11(8):BE01-BE05. doi: 10.7860/JCDR/2017/26748.10469.
  12. Hoffman W., Lakkis F.G., Cells B. Antibodies, and More. Clin J Am Soc Nephrol. 2016;11(1):137-54. doi: 10.2215/CJN.09430915.
  13. Агеева Е.С., Штыгашева О.В., Рязанцева Н.В., Цуканов В.В. Молекулярно-генетические факторы, влияющие на исход инфицирования Heiicobacter pyiori у жителей Республики Хакасия. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2010;20(4):16-21.
  14. McMahon B.J., Bruce M.G., Koch A., et ai. The diagnosis and treatment of Heiicobacter pyiori infection in Arctic regions with a high prevaience of infection: Expert Commentary Epidemioi Infect. 2016;144(2):225-33. Doi: 10.1017/ S0950268815001181.
  15. Агеева Е.С., Штыгашева О.В., Цуканов В.В., Рязанцева Н.В. Иммунологические особенности течения гастродуоденальной патологии у жителей Хакасии. Иммунология. 2009;30(3):162-64.
  16. Cappeiiesso R., Fassan M., Hanspeter E., et ai. HER2 status in gastroesophageai cancer: a tissue microarray study of 1040 cases. Hum Pathoi. 2015;46(5):665-72. Doi: 10.1016/j. humpath.2015.02.007.
  17. Цуканов В.В., Васютин А.В., Тонких Ю.Л. и др. Иммунологические аспекты патогенеза атрофического гастрита. Врач. 2019;30(5):47-50. doi: 10.29296/25877305-2019-05-08.
  18. Buommino E., Donnarumma G., Manente L., et ai. The Heiicobacter pyiori protein HspB interferes with Nrf2/Keap1 pathway aitering the antioxidant response of Ags ceiis. Heiicobacter. 2012;17(6):417-25. doi: 10.1111/j.1523-53 78.2012.00973.x.
  19. Цуканов В.В. Смирнова О.В., Каспаров Э.В. и др. Изменения показателей прооксидантной и антиоксидантной систем в плазме крови у муж чин при атрофическом гастрите и раке желудка. Терапевтический архив. 2018;90(2):24-7. doi: 10.26442/terarkh201890224-27.
  20. Pimentei-Nunes P., Libânio D., Marcos-Pinto R., et ai. Management of epitheiiai precancerous conditions and iesions in the stomach (MAPS II): European Society of Gastrointestinai Endoscopy (ESGE), European Heiicobacter and Microbiota Study Group (EHMSG), European Society of Pathoiogy (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideiine update 2019. Endoscopy. 2019;51(4):365-88.
  21. Sugano K., Tack J., Kuipers E.J., et al. Kyoto giobai consensus report on Heiicobacter pyiori gastritis. Gut. 2015;64(9):1353-67. Doi: 10.1136/ gutjni-2015-309252.
  22. Maifertheiner P., Megraud F., O'Morain C.A., et al. Management of Heiicobacter pyiori infection-the Maastricht V/Fiorence Consensus Report. Gut. 2017;66(1):6-30. Doi: 10.1136/ gutjni-2016-312288.
  23. Бордин Д.С., Янова О.Б., Абдулхаков Р.А. и др. Европейский регистр Heiicobacter pyiori (протокол Hp-EuReg): первые результаты российских центров. Терапевтический архив. 2016;88(2): 33-8. doi: 10.17116/terarkh201688233-38.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies